Found: 92
Select item for more details and to access through your institution.
Targeting wild-type TP53 using AMG 232 in combination with MAPK inhibition in Metastatic Melanoma; a phase 1 study.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 5, p. 1051, doi. 10.1007/s10637-022-01253-3
- By:
- Publication type:
- Article
Proteasomal down-regulation of the proapoptotic MST2 pathway contributes to BRAF inhibitor resistance in melanoma.
- Published in:
- Life Science Alliance, 2022, v. 5, n. 10, p. 1, doi. 10.26508/lsa.202201445
- By:
- Publication type:
- Article
Adjuvant therapy in patients with sarcomatoid renal cell carcinoma: post hoc analysis from Eastern Cooperative Oncology Group‐American College of Radiology Imaging Network (ECOG‐ACRIN) E2805.
- Published in:
- BJU International, 2022, v. 129, n. 6, p. 718, doi. 10.1111/bju.15587
- By:
- Publication type:
- Article
Author Correction: Reversal of pre-existing NGFR-driven tumor and immune therapy resistance.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Feeling energetic? New strategies to prevent metabolic reprogramming in melanoma.
- Published in:
- Experimental Dermatology, 2015, v. 24, n. 9, p. 657, doi. 10.1111/exd.12763
- By:
- Publication type:
- Article
MicroRNA expression profiling predicts clinical outcome of carboplatin/paclitaxel-based therapy in metastatic melanoma treated on the ECOG-ACRIN trial E2603.
- Published in:
- Clinical Epigenetics, 2015, v. 7, n. 1, p. 1, doi. 10.1186/s13148-015-0092-2
- By:
- Publication type:
- Article
One Hippo and many masters: differential regulation of the Hippo pathway in cancer.
- Published in:
- Biochemical Society Transactions, 2014, v. 42, n. 4, p. 816, doi. 10.1042/BST20140030
- By:
- Publication type:
- Article
The impact of timing of immunotherapy with cranial irradiation in melanoma patients with brain metastases: intracranial progression, survival and toxicity.
- Published in:
- Journal of Neuro-Oncology, 2018, v. 138, n. 2, p. 299, doi. 10.1007/s11060-018-2795-7
- By:
- Publication type:
- Article
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion.
- Published in:
- Nature, 2012, v. 487, n. 7408, p. 500, doi. 10.1038/nature11183
- By:
- Publication type:
- Article
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E).
- Published in:
- Nature, 2011, v. 480, n. 7377, p. 387, doi. 10.1038/nature10662
- By:
- Publication type:
- Article
Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure.
- Published in:
- EMBO Molecular Medicine, 2017, v. 9, n. 8, p. 1011, doi. 10.15252/emmm.201607156
- By:
- Publication type:
- Article
Correction: Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment.
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice
The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.
- Published in:
- Nature Genetics, 2015, v. 47, n. 3, p. 250, doi. 10.1038/ng.3218
- By:
- Publication type:
- Article
A phase I, dose escalation trial of ZD0473, a novel platinum analogue, in combination with gemcitabine.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2004, v. 53, n. 5, p. 404, doi. 10.1007/s00280-003-0754-1
- By:
- Publication type:
- Article
Phase I trial of the antifolate ZD9331 in combination with cisplatin in patients with refractory solid malignancies.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2004, v. 53, n. 4, p. 357, doi. 10.1007/s00280-003-0735-4
- By:
- Publication type:
- Article
Phase I combination trial of gemcitabine, paclitaxel, and carboplatin in patients with advanced malignancy.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2003, v. 52, n. 3, p. 217, doi. 10.1007/s00280-003-0640-x
- By:
- Publication type:
- Article
The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design.
- Published in:
- 2020
- By:
- Publication type:
- journal article
The Conundrum of Genetic "Drivers" in Benign Conditions.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Antitumor Activity of BRAF Inhibitor and IFNα Combination in BRAF-Mutant Melanoma.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Genetic Alterations and Personalized Medicine in Melanoma: Progress and Future Prospects.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2014, v. 106, n. 2, p. 1, doi. 10.1093/jnci/djt435
- By:
- Publication type:
- Article
Biological challenges of BRAF inhibitor therapy
- Published in:
- Molecular Oncology, 2011, v. 5, n. 2, p. 116, doi. 10.1016/j.molonc.2011.01.005
- By:
- Publication type:
- Article
Efficacy and Safety of Trametinib in Non‐V600 BRAF Mutant Melanoma: A Phase II Study.
- Published in:
- Oncologist, 2021, v. 26, n. 9, p. 731, doi. 10.1002/onco.13795
- By:
- Publication type:
- Article
Upfront Surgical Resection of Melanoma Brain Metastases Provides a Bridge Toward Immunotherapy‐Mediated Systemic Control.
- Published in:
- Oncologist, 2019, v. 24, n. 5, p. 671, doi. 10.1634/theoncologist.2018-0306
- By:
- Publication type:
- Article
Impact of Age on Outcomes with Immunotherapy for Patients with Melanoma.
- Published in:
- Oncologist, 2017, v. 22, n. 8, p. 963, doi. 10.1634/theoncologist.2016-0450
- By:
- Publication type:
- Article
Academic Cancer Center Phase I Program Development.
- Published in:
- Oncologist, 2017, v. 22, n. 4, p. 369, doi. 10.1634/theoncologist.2016-0409
- By:
- Publication type:
- Article
Phase I/II Trial of Imatinib and Bevacizumab in Patients With Advanced Melanoma and Other Advanced Cancers.
- Published in:
- Oncologist, 2015, v. 20, n. 8, p. 952, doi. 10.1634/theoncologist.2015-0108
- By:
- Publication type:
- Article
A Phase I Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma.
- Published in:
- Oncologist, 2015, v. 20, n. 6, p. 617, doi. 10.1634/theoncologist.2015-0105
- By:
- Publication type:
- Article
Ipilimumab for Patients With Advanced Mucosal Melanoma.
- Published in:
- Oncologist, 2013, v. 18, n. 6, p. 726, doi. 10.1634/theoncologist.2012-0464
- By:
- Publication type:
- Article
A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status.
- Published in:
- Cancer Medicine, 2017, v. 6, n. 8, p. 1904, doi. 10.1002/cam4.1140
- By:
- Publication type:
- Article
Pathway signatures derived from on-treatment tumor specimens predict response to anti-PD1 blockade in metastatic melanoma.
- Published in:
- Nature Communications, 2021, v. 12, n. 1, p. 1, doi. 10.1038/s41467-021-26299-4
- By:
- Publication type:
- Article
SARS-CoV-2 viral load is associated with increased disease severity and mortality.
- Published in:
- Nature Communications, 2020, v. 11, n. 1, p. 1, doi. 10.1038/s41467-020-19057-5
- By:
- Publication type:
- Article
Clinical Profiling of BCL-2 Family Members in the Setting of BRAF Inhibition Offers a Rationale for Targeting <i>De Novo</i> Resistance Using BH3 Mimetics.
- Published in:
- PLoS ONE, 2014, v. 9, n. 7, p. 1, doi. 10.1371/journal.pone.0101286
- By:
- Publication type:
- Article
An Active Learning Approach for Rapid Characterization of Endothelial Cells in Human Tumors.
- Published in:
- PLoS ONE, 2014, v. 9, n. 3, p. 1, doi. 10.1371/journal.pone.0090495
- By:
- Publication type:
- Article
Expression of Drug Targets in Patients Treated with Sorafenib, Carboplatin and Paclitaxel.
- Published in:
- PLoS ONE, 2013, v. 8, n. 8, p. 1, doi. 10.1371/journal.pone.0069748
- By:
- Publication type:
- Article
The Anti-Melanoma Activity of Dinaciclib, a Cyclin-Dependent Kinase Inhibitor, Is Dependent on p53 Signaling.
- Published in:
- PLoS ONE, 2013, v. 8, n. 3, p. 1, doi. 10.1371/journal.pone.0059588
- By:
- Publication type:
- Article
A Melanoma Molecular Disease Model.
- Published in:
- PLoS ONE, 2011, v. 6, n. 3, p. 1, doi. 10.1371/journal.pone.0018257
- By:
- Publication type:
- Article
A randomized study of genetic education versus usual care in tumor profiling for advanced cancer in the ECOG‐ACRIN Cancer Research Group (EAQ152).
- Published in:
- Cancer (0008543X), 2022, v. 128, n. 7, p. 1381, doi. 10.1002/cncr.34063
- By:
- Publication type:
- Article
A melanocyte lineage program confers resistance to MAP kinase pathway inhibition.
- Published in:
- Nature, 2013, v. 504, n. 7478, p. 138, doi. 10.1038/nature12688
- By:
- Publication type:
- Article
From genes to drugs: targeted strategies for melanoma.
- Published in:
- Nature Reviews Cancer, 2012, v. 12, n. 5, p. 349, doi. 10.1038/nrc3218
- By:
- Publication type:
- Article
Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors.
- Published in:
- Scientific Reports, 2017, p. 44123, doi. 10.1038/srep44123
- By:
- Publication type:
- Article
STAG2 regulates interferon signaling in melanoma via enhancer loop reprogramming.
- Published in:
- Nature Communications, 2022, v. 13, n. 1, p. 1, doi. 10.1038/s41467-022-29541-9
- By:
- Publication type:
- Article
TORC1 Suppression Predicts Responsiveness to RAF and MEK Inhibition in BRAF-Mutant Melanoma.
- Published in:
- Science Translational Medicine, 2013, v. 5, n. 196, p. 1, doi. 10.1126/scitranslmed.3005753
- By:
- Publication type:
- Article
A twenty year perspective on melanoma therapy.
- Published in:
- Pigment Cell & Melanoma Research, 2023, v. 36, n. 6, p. 563, doi. 10.1111/pcmr.13125
- By:
- Publication type:
- Article
A PAX3/BRN2 rheostat controls the dynamics of BRAF mediated MITF regulation in MITF<sup>high</sup>/AXL<sup>low</sup> melanoma.
- Published in:
- Pigment Cell & Melanoma Research, 2019, v. 32, n. 2, p. 280, doi. 10.1111/pcmr.12741
- By:
- Publication type:
- Article
Micro RNA-125a promotes resistance to BRAF inhibitors through suppression of the intrinsic apoptotic pathway.
- Published in:
- Pigment Cell & Melanoma Research, 2017, v. 30, n. 3, p. 328, doi. 10.1111/pcmr.12578
- By:
- Publication type:
- Article
The state of melanoma: challenges and opportunities.
- Published in:
- Pigment Cell & Melanoma Research, 2016, v. 29, n. 4, p. 404, doi. 10.1111/pcmr.12475
- By:
- Publication type:
- Article
Effectively targeting CRAF: rational serendipity targeting SRC?
- Published in:
- Pigment Cell & Melanoma Research, 2015, v. 28, n. 3, p. 242, doi. 10.1111/pcmr.12360
- By:
- Publication type:
- Article
Wnt5 A promotes an adaptive, senescent-like stress response, while continuing to drive invasion in melanoma cells.
- Published in:
- Pigment Cell & Melanoma Research, 2015, v. 28, n. 2, p. 184, doi. 10.1111/pcmr.12330
- By:
- Publication type:
- Article
Biology of advanced uveal melanoma and next steps for clinical therapeutics.
- Published in:
- Pigment Cell & Melanoma Research, 2015, v. 28, n. 2, p. 135, doi. 10.1111/pcmr.12304
- By:
- Publication type:
- Article
Cyclin-dependent kinases as therapeutic targets in melanoma.
- Published in:
- Pigment Cell & Melanoma Research, 2014, v. 27, n. 3, p. 351, doi. 10.1111/pcmr.12211
- By:
- Publication type:
- Article